Anzeige
Mehr »
Donnerstag, 26.06.2025 - Börsentäglich über 12.000 News
Ein echter Gamechanger: Diese News kann den Grundstein für eine Neubewertung der Rock-Tech-Aktie legen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EJH8 | ISIN: FR001400K4B1 | Ticker-Symbol: 2E40
Frankfurt
19.06.25 | 19:44
0,020 Euro
0,00 % 0,000
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
PHAXIAM THERAPEUTICS SA Chart 1 Jahr
5-Tage-Chart
PHAXIAM THERAPEUTICS SA 5-Tage-Chart
RealtimeGeldBriefZeit
0,1000,11117:33

Aktuelle News zur PHAXIAM THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
19.06.XFRA 2E40: AUSSETZUNG/SUSPENSION1.072DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILPHAXIAM THERAPEUT....
► Artikel lesen
18.06.PHAXIAM Therapeutics Announces the Suspension of Trading in Its Shares Until Delisting250Regulatory News: PHAXIAM Therapeutics (Euronext: PHXM FR001400K4B1), hereinafter referred to as "the Company" or "PHAXIAM," a biopharmaceutical company specializing in the development of innovative...
► Artikel lesen
PHAXIAM THERAPEUTICS Aktie jetzt für 0€ handeln
12.06.PHAXIAM Therapeutics Announces Judicial Liquidation and Delisting263Regulatory News: PHAXIAM Therapeutics (Euronext: PHXM FR001400K4B1), hereinafter referred to as "the Company" or "PHAXIAM," a biopharmaceutical company specializing in the development of innovative...
► Artikel lesen
05.06.PHAXIAM Therapeutics: New Postponement of the Offer Review Hearing329Regulatory News: PHAXIAM Therapeutics (Euronext: PHXM FR001400K4B1), a biopharmaceutical company ("the Company" or "PHAXIAM") developing innovative treatments for severe and resistant bacterial...
► Artikel lesen
22.05.PHAXIAM Therapeutics: Postponement of the Offer Review Hearing334Regulatory News: PHAXIAM Therapeutics (Euronext: PHXM FR001400K4B1), a biopharmaceutical company ("the Company" or "PHAXIAM") developing innovative treatments for severe and resistant bacterial...
► Artikel lesen
05.05.PHAXIAM Therapeutics: Extension of the Observation Period of the Receivership Procedure312Regulatory News: PHAXIAM Therapeutics (Euronext: PHXM FR001400K4B1), a biopharmaceutical company ("the Company" or "PHAXIAM") developing innovative treatments for severe and resistant bacterial...
► Artikel lesen
24.04.PHAXIAM Therapeutics: Update on the Receivership Procedure307Regulatory News: PHAXIAM Therapeutics (Euronext: PHXM FR001400K4B1), a biopharmaceutical company ("the Company" or "PHAXIAM") developing innovative treatments for severe and resistant bacterial...
► Artikel lesen
24.03.XFRA 2E40: WIEDERAUFNAHME/RESUMPTION299FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME...
► Artikel lesen
14.03.PHAXIAM THERAPEUTICS Announces the Launch of a Process to Find Buyers in the Context of its Receivership Procedure418Regulatory News: PHAXIAM Therapeutics (Euronext: PHXM FR001400K4B1), a biopharmaceutical company ("PHAXIAM" or "the Company") developing innovative treatments for severe and resistant bacterial...
► Artikel lesen
06.03.XFRA 2E40: AUSSETZUNG/SUSPENSION248DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILPHAXIAM THERAPEUT....
► Artikel lesen
06.03.PHAXIAM Therapeutics Announces the Opening of a Receivership Procedure and the Postponement of its 2024 Financial Results Publication371Regulatory News: PHAXIAM Therapeutics (Euronext: PHXM FR001400K4B1), a biopharmaceutical company ("PHAXIAM" or "the Company") developing innovative treatments for severe and resistant bacterial...
► Artikel lesen
06.03.PHAXIAM Therapeutics: Press Release Regarding Suspension of Trading328Regulatory News: PHAXIAM Therapeutics (Euronext: PHXM FR001400K4B1), has requested Euronext to suspend the trading of its stock listed on the Euronext Paris market from the publication of this...
► Artikel lesen
31.01.PHAXIAM Therapeutics: PHAXIAM Provides An Update On The Deployment Of Its Strategy To Maximize The Development Potential Of Phage Therapy580Strategy built around two complementary development axes: GMP Individualized Phage Therapies (IPT) and Phage Therapies Medicinal Products (PTMP), to maximize access to phage therapy care ...
► Artikel lesen
30.01.PHAXIAM Therapeutics and Technophage Enter Strategic Collaboration On Individualized GMP Phages Therapies (IPT) Against Bacteria Responsible For ~ 70%(1) Of The Most Common Severe Resistant Infections528Combined 25 GMP(2) Phages Portfolio to cover by end 2025 five of the most critical pathogens (S. aureus, P. aeruginosa, E. coli, K. pneumoniae, A. baumannii) and expansion by end 2026 to 35-45...
► Artikel lesen
13.01.PHAXIAM Therapeutics Announces Its Financial Calendar for 2025483Regulatory News: PHAXIAM Therapeutics (Euronext: PHXM FR0011471135), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today announces...
► Artikel lesen
07.01.PHAXIAM Therapeutics Announces Updated Real-Life Clinical Data From Patients Treated Under the Compassionate Status in Europe443Promising clinical results observed in the first 88 patients evaluated so far, confirming the safety and an important clinical benefit for patients Control of the infection at 3 months...
► Artikel lesen
06.01.PHAXIAM: Monthly Information Related to Total Number of Voting Rights and Shares Composing the Share Capital - December 31, 2024369Article 223-16 of general regulation of French Autorité des Marchés Financiers Regulatory News: PHAXIAM (Paris:PHXM): Listing market: Euronext Paris (Market segment C ISIN Code: FR001400K4B1-...
► Artikel lesen
30.12.24PHAXIAM Therapeutics Presents Clinical Data of the PhagoDAIR Pilot Study, With Results Confirming the Design of the GLORIA Phase II Clinical Study710This non-comparative1 pilot study, including patients with Prosthetic Joint Infections (PJI), recruited 29 patients, 26 of whom were evaluable for clinical activity, out of the 64 initially planned...
► Artikel lesen
27.11.24Phaxiam Therapeutics S.A.: PHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy area292Webinar being held today "Evolving strategic context for phages, Introducing new opportunities" to present PHAXIAM Therapeutics strategyBased on the positive evolution in phages therapy market, PHAXIAM's...
► Artikel lesen
18.11.24Phaxiam Therapeutics S.A.: PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day"338PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day" This event, organized in collaboration with Phage Canada and bringing together international...
► Artikel lesen
Weiter >>
25 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,4